Cargando…
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
The coronavirus disease 2019 (COVID-19) pandemic is having a major clinical as well as organisational impact on the national health-care system in Italy, particularly in high-volume hospitals which are usually active for many essential clinical needs, including inflammatory bowel disease (IBD). Here...
Autores principales: | Scaldaferri, Franco, Pugliese, Daniela, Privitera, Giuseppe, Onali, Sara, Lopetuso, Loris Riccardo, Rizzatti, Gianenrico, Settanni, Carlo Romano, Pizzoferrato, Marco, Schiavoni, Elisa, Turchini, Laura, Amatucci, Valeria, Napolitano, Daniele, Bernabei, Tiziana, Mora, Vincenzina, Laterza, Lucrezia, Papa, Alfredo, Guidi, Luisa, Rapaccini, Gian Lodovico, Gasbarrini, Antonio, Armuzzi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435006/ https://www.ncbi.nlm.nih.gov/pubmed/32438878 http://dx.doi.org/10.1177/2050640620929133 |
Ejemplares similares
-
Orphan patients with inflammatory bowel disease - when we treat beyond evidence
por: Privitera, Giuseppe, et al.
Publicado: (2021) -
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021) -
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021) -
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
por: Papa, Alfredo, et al.
Publicado: (2022) -
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
por: Holleran, Grainne, et al.
Publicado: (2017)